Pelitinib
- Generic Name
- Pelitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23ClFN5O2
- CAS Number
- 257933-82-7
- Unique Ingredient Identifier
- X5DWL380Z6
- Background
Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
- Indication
Investigated for use/treatment in colorectal cancer and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098501
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath